SBIR-STTR Award

Generating a Library of Antimicrobial R-Type Pyocins Against Enteric Bacteria
Award last edited on: 7/14/14

Sponsored Program
SBIR
Awarding Agency
NIH : NIAID
Total Award Amount
$373,250
Award Phase
2
Solicitation Topic Code
-----

Principal Investigator
Dean M Scholl

Company Information

AvidBiotics Corporation

100 Kimball Way
South San Francisco, CA 94080
   (650) 873-1234
   dmartin@avidbiotics.com
   www.avidbiotics.com
Location: Single
Congr. District: 15
County: San Mateo

Phase I

Contract Number: 1R21AI085318-01
Start Date: 9/23/10    Completed: 8/31/12
Phase I year
2010
Phase I Amount
$200,000
Our proposal is to develop a platform of R-type pyocins as bactericidal agents that can be engineered to be remarkably pathogen-specific, while versatile enough to enable rapid modification of their specificity towards a diverse range of pathogenic bacteria. Specifically, we will generate a battery of highly specific therapeutic and prophylactic agents targeting STEC serogroups O26, O45, O55, O91, O103, O111, O113, O118, O121, O145, O146, as well as Salmonella enterica serogroup D1, including serotypes enteriditis and typhi, and Vibrio cholera serotypes O1 and O139. The work proposed is based on our findings that R-type pyocins are highly specific and highly potent bactericidal protein complexes that have been shown to be efficacious for systemic bacterial infections in animals. While highly specific to their target organism, we have shown that these bactericidal agents can be retargeted to other bacteria by modifying their tail fibers with the related tail proteins of bacteriophages. We therefore hypothesize that R-type pyocins can be used as a versatile platform to target a broad range of human pathogenic bacteria. The ubiquity and diversity of phages specific against virtually every type of bacteria, promise broad utility for this platform. In order to achieve our goals, we will first isolate Podoviridae bacteriophages that recognize and kill the pathogen of interest and identify its tail fiber (Specific Aim #1). That tail fiber will then be fused to a truncated native tail fiber of the R2-type pyocin and expressed together with the remaining pyocin genome, creating a viable pyocin with altered specificity against the pathogen of interest (Specific Aim #2) This portfolio of potent, targeted bactericidal agents will have broad applications in the management of the public health and clinical aspects of widespread infection by these enteric pathogens. These specific therapeutic agents could be used to manage accidental or intentional, large- or small scale infections. Due to their extraordinary specificity, they are expected to eliminate the target pathogens while leaving normal, healthy, microflora intact. Importantly, given the diversity of bacteriophages available against a wide array of bacteria, this versatile platform can be developed for specificities far beyond what is proposed herein, have far wider applicability against nearly all known bacteria.

Public Health Relevance:
We propose to develop a versatile, pure protein-based platform for defense against a diverse array of dangerous bacteria that cause severe intestinal infections and potentially death. Our platform, based on altering the binding and killing specificity of the basic R-type pyocin structure by attaching only the specific tail proteins of bacterial viruses, offers a potent response to a wide range of pathogens which pose a threat to public health in the form of accidental or intentional food- or waterborne outbreak.

Public Health Relevance Statement:
Narrative We propose to develop a versatile, pure protein-based platform for defense against a diverse array of dangerous bacteria that cause severe intestinal infections and potentially death. Our platform, based on altering the binding and killing specificity of the basic R-type pyocin structure by attaching only the specific tail proteins of bacterial viruses, offers a potent response to a wide range of pathogens which pose a threat to public health in the form of accidental or intentional food- or waterborne outbreak.

NIH Spending Category:
Biodefense; Digestive Diseases; Emerging Infectious Diseases; Food Safety; Infectious Diseases

Project Terms:
Animal Model; Animals; antimicrobial; Bacteria; Bacterial Infections; bactericide; bacteriocin; Bacteriophages; base; Binding (Molecular Function); Catalytic Domain; Cell Surface Receptors; Cessation of life; Clinical; Disease Outbreaks; Engineering; enteric pathogen; Enterobacteriaceae; Escherichia coli; Escherichia coli O157; Family; Fiber; Food Safety; foodborne; Genes; Genome; genome sequencing; Goals; Human; Infection; interest; Intestines; K antigen; Killings; Left; Libraries; Location; Methods; Modification; Molecular Weight; Mus; novel; O Antigens; Organism; particle; pathogen; pathogenic bacteria; Podoviridae; prophylactic; protein complex; Protein Subunits; Proteins; Pseudomonas aeruginosa; public health medicine (field); public health relevance; receptor binding; response; Salmonella; Salmonella enterica; Serotyping; Shiga Toxin; Specificity; Structure; Tail; Technology; Testing; Therapeutic; Therapeutic Agents; Vibrio cholerae; waterborne; Work; Yersinia pestis

Phase II

Contract Number: 5R21AI085318-02
Start Date: 9/23/10    Completed: 8/31/12
Phase II year
2011
Phase II Amount
$173,250
Our proposal is to develop a platform of R-type pyocins as bactericidal agents that can be engineered to be remarkably pathogen-specific, while versatile enough to enable rapid modification of their specificity towards a diverse range of pathogenic bacteria. Specifically, we will generate a battery of highly specific therapeutic and prophylactic agents targeting STEC serogroups O26, O45, O55, O91, O103, O111, O113, O118, O121, O145, O146, as well as Salmonella enterica serogroup D1, including serotypes enteriditis and typhi, and Vibrio cholera serotypes O1 and O139. The work proposed is based on our findings that R-type pyocins are highly specific and highly potent bactericidal protein complexes that have been shown to be efficacious for systemic bacterial infections in animals. While highly specific to their target organism, we have shown that these bactericidal agents can be retargeted to other bacteria by modifying their tail fibers with the related tail proteins of bacteriophages. We therefore hypothesize that R-type pyocins can be used as a versatile platform to target a broad range of human pathogenic bacteria. The ubiquity and diversity of phages specific against virtually every type of bacteria, promise broad utility for this platform. In order to achieve our goals, we will first isolate Podoviridae bacteriophages that recognize and kill the pathogen of interest and identify its tail fiber (Specific Aim #1). That tail fiber will then be fused to a truncated native tail fiber of the R2-type pyocin and expressed together with the remaining pyocin genome, creating a viable pyocin with altered specificity against the pathogen of interest (Specific Aim #2) This portfolio of potent, targeted bactericidal agents will have broad applications in the management of the public health and clinical aspects of widespread infection by these enteric pathogens. These specific therapeutic agents could be used to manage accidental or intentional, large- or small scale infections. Due to their extraordinary specificity, they are expected to eliminate the target pathogens while leaving normal, healthy, microflora intact. Importantly, given the diversity of bacteriophages available against a wide array of bacteria, this versatile platform can be developed for specificities far beyond what is proposed herein, have far wider applicability against nearly all known bacteria.

Public Health Relevance:
We propose to develop a versatile, pure protein-based platform for defense against a diverse array of dangerous bacteria that cause severe intestinal infections and potentially death. Our platform, based on altering the binding and killing specificity of the basic R-type pyocin structure by attaching only the specific tail proteins of bacterial viruses, offers a potent response to a wide range of pathogens which pose a threat to public health in the form of accidental or intentional food- or waterborne outbreak.

Public Health Relevance Statement:
Narrative We propose to develop a versatile, pure protein-based platform for defense against a diverse array of dangerous bacteria that cause severe intestinal infections and potentially death. Our platform, based on altering the binding and killing specificity of the basic R-type pyocin structure by attaching only the specific tail proteins of bacterial viruses, offers a potent response to a wide range of pathogens which pose a threat to public health in the form of accidental or intentional food- or waterborne outbreak.

NIH Spending Category:
Biodefense; Digestive Diseases; Emerging Infectious Diseases; Food Safety; Infectious Diseases

Project Terms:
Animal Model; Animals; antimicrobial; Bacteria; Bacterial Infections; bactericide; bacteriocin; Bacteriophages; base; Binding (Molecular Function); Catalytic Domain; Cell Surface Receptors; Cessation of life; Clinical; Disease Outbreaks; Engineering; enteric pathogen; Enterobacteriaceae; Escherichia coli; Escherichia coli EHEC; Escherichia coli O157; Family; Fiber; Food Safety; foodborne; Genes; Genome; genome sequencing; Goals; Human; Infection; interest; Intestines; K antigen; Killings; Left; Libraries; Location; Methods; Modification; Molecular Weight; Mus; novel; O Antigens; Organism; particle; pathogen; pathogenic bacteria; Podoviridae; prophylactic; protein complex; Protein Subunits; Proteins; Pseudomonas aeruginosa; public health medicine (field); public health relevance; receptor binding; response; Salmonella; Salmonella enterica; Serotyping; Shiga Toxin; Specificity; Structure; Tail; Technology; Testing; Therapeutic; Therapeutic Agents; Vibrio cholerae; waterborne; Work; Yersinia pestis